慧创医疗 focuses on research in near-infrared (fNIRS) brain functional imaging and evaluation to provide multidimensional, quantitative brain function imaging solutions for diagnosis and treatment of brain diseases. The company positions its core product around fNIRS-based brain functional imaging. It recently completed a nearly RMB 100 million B+ financing round. Proceeds will be used to strengthen the company’s market-leading brand position for fNIRS brain functional imaging. The funds will also support clinical trials of transcranial light-regulation therapy for degenerative diseases and team recruitment and expansion. Changhai Capital continues to serve as the company’s exclusive financial advisor. 慧创医疗 focuses on research and product development in near‑infrared (fNIRS) brain functional imaging and evaluation. The company provides multidimensional, quantitative brain functional imaging solutions to support diagnosis and treatment of brain diseases. It recently completed a B round of financing exceeding ¥100 million. The financing was led by Zhongke Haichuang, with participation from Yida Capital, existing investor Qingyuan Investment, and Daoyuan Capital. Proceeds will be used to advance brand building for its fNIRS brain function imaging products and to support clinical trials of transcranial light‑based modulation treatments for degenerative diseases. Changhai Capital served as the exclusive financial advisor on the transaction.

Total raised

$27M

Funding rounds

2

Latest round

Series B

Latest activity

May 2024